VisionSeq, a leader in the field of precision medicine for infections, recently announced the closing of RMB 200 Million in its Series C financing. The round was led by Tencent, with participation from existing shareholders including CICC Capital, CDH Investments, and Cash Capital. This marks the second round of financing within six months, following VisionSeq's RMB 200 million B financing in August 2020. The funds from this round will continue to support product research and development, medical device product registration, strengthening medical brand marketing, and enhancing clinical services.

CEC Capital Group continues to serve as the exclusive financial advisor for VisionSeq in this transaction.

Founded in 2018, VisionSeq specializes in genetic technology innovation and precision medicine for infections, targeting clinical departments such as ICU, infection, respiratory, pediatrics, and neurology. The company has developed an infection AI diagnostic system based on genomics, imaging omics, and EMR, providing comprehensive precision diagnostic solutions for infectious diseases in clinical settings.